

Prevention Of lymphoedema by Therapeutic Elastic Compression hoses: Treatment efficacy

Submission date 02/05/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 02/05/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 23/09/2021	Condition category Surgery	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr M.M. Stuiver

Contact details
The Netherlands Cancer Institute
Antoni van Leeuwenhoek Hospital
Department of Physiotherapy
Amsterdam
Netherlands
1066 CX
+31 (0)20 512 2586
m.stuiver@nki.nl

Additional identifiers

Protocol serial number
NL917 (NTR941)

Study information

Scientific Title
Prevention Of lymphoedema by Therapeutic Elastic Compression hoses: Treatment efficacy

Acronym
PROTECT

Study objectives

H0: incidence of lymphoedema in hose-group equals non-hose group.
H1: incidence of lymphoedema in hose group does not equal non-hose group.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approval received from the Medical Ethical Committee of The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital on the 4th September 2006 (ref: PTC06.1170/MO6PRO).

Study design
Randomised, active controlled, parallel group, multicentre trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Compression hoses, lymphoedema, inguinal lymph node dissection

Interventions
Therapeutic elastic compression hose for a period of six months, in addition to standard regimen of early ambulation and patient education.

Intervention Type
Procedure/Surgery

Phase
Not Specified

Primary outcome(s)
Incidence of lymphoedema (survival without lymphoedema); surface measurements are used to calculate limb volume to establish the diagnosis of lymphoedema at T0, T1, T2, T3, T4 and T5.

Key secondary outcome(s)

1. Early surgical complications (wound breakdown, lymphocele formation, wound infection), measured at T2
2. Genital oedema, measured at T0, T1, T2, T3, T4 and T5
3. Health related quality of life, measured at T0, T4 and T5
4. Body image, measured at T4 and T5
5. Compliance to usage of the hose, measured at T2, T3 and T4
6. Use of professional homecare
7. Lymphoedema requiring treatment

T0: day of admittance
T1: day of dismissal
T2: first outpatient visit two months after dismissal
T3: second outpatient visit four months after dismissal
T4: third outpatient visit six months after dismissal
T5: fourth outpatient visit 12 months after dismissal

Completion date

31/12/2007

Eligibility

Key inclusion criteria

1. 18 years or older
2. Inguinal lymph node dissection because of metastases of melanoma or urogenital tumour

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Not Specified

Key exclusion criteria

1. Deep venous thrombosis
2. Manifest lymphoedema or episodes of lymphoedema in the past
3. Isolated limb perfusion treatment
4. Oedema as a result of venous insufficiency
5. Psychiatric disorders
6. Lacking basic proficiency in Dutch
7. Skin diseases of the leg

Date of first enrolment

01/10/2006

Date of final enrolment

31/12/2007

Locations

Countries of recruitment

Netherlands

Study participating centre
The Netherlands Cancer Institute
Amsterdam
Netherlands
1066 CX

Sponsor information

Organisation
Netherlands Cancer Institute (NKI) (The Netherlands)

ROR
<https://ror.org/03xqtf034>

Funder(s)

Funder type
Research organisation

Funder Name
Netherlands Cancer Institute (NKI) (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration